Clinical Trials for Non-Small Cell Lung Cancer

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic NSCLC lacking EGFR, ALK, or ROS1 alterations and generally progressing after checkpoint inhibition and platinum chemotherapy receive LN-145 (lifileucel), autologous tumor-derived T cells expanded ex vivo, after lymphodepleting chemotherapy, followed by interleukin-2.

ClinicalTrials.gov ID: NCT04614103

A Phase I Open-label, Multi-dose, Dose Escalation and Dose Expansion Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced EGFR-mutated NSCLC, including exon 20 insertions, exon 19 deletions, L858R, and uncommon mutations, receive oral PLB1004 (andamertinib) monotherapy. PLB1004 is an irreversible, mutation-selective EGFR tyrosine kinase inhibitor; dosing is escalated and then expanded to assess safety and preliminary antitumor activity.

ClinicalTrials.gov ID: NCT06046495

KB707-02: a Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced solid tumors affecting the lungs after progression on, intolerance of, or refusal of standard therapy receive inhaled KB707, a non-integrating HSV-1 vector designed to express IL-12 and IL-2 locally. Separate cohorts of patients with stage III/IV NSCLC receive KB707 with pembrolizumab, with or without chemotherapy.

ClinicalTrials.gov ID: NCT06228326

Safety and Efficacy of Ivonescimab and Chemotherapy Plus Stereotactic Radiosurgery (SRS) in the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with squamous or nonsquamous NSCLC, at least one SRS-eligible brain metastasis (1.0–3.5 cm), and ECOG performance status 0–1 receive chemotherapy plus ivonescimab, a bispecific antibody targeting PD-1 and VEGF-A, followed by three-fraction SRS. The study evaluates a tolerable ivonescimab dose and 3-month intracranial disease control.

ClinicalTrials.gov ID: NCT07535463

A Pilot Study of Tepotinib + Ivonescimab in Patients With Advanced METex14 Skipping Positive NSCLC

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced or recurrent MET exon 14–skipping NSCLC receive tepotinib, a MET inhibitor, plus investigational ivonescimab, a bispecific antibody targeting PD-1 and VEGF-A. Prior MET inhibitors and checkpoint inhibitors are permitted; the study focuses on safety and identifying a tolerable tepotinib dose.

ClinicalTrials.gov ID: NCT07619339

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with advanced or metastatic urothelial carcinoma after at least one prior regimen, including those previously treated with enfortumab vedotin, or selected other solid tumors after standard options are exhausted receive intravenous LY4052031. This investigational Nectin-4–targeted antibody–drug conjugate delivers a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06465069

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic solid tumors and ECOG performance status 0–1 receive MDNA11 alone or with pembrolizumab. MDNA11 is a long-acting IL-2 agonist designed to favor IL-2 receptor β signaling in CD8-positive T cells and natural killer cells while limiting regulatory T-cell stimulation; pembrolizumab blocks PD-1.

ClinicalTrials.gov ID: NCT05086692

A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum-resistant high-grade ovarian cancer or relapsed/refractory lung adenocarcinoma who have exhausted beneficial standard options receive intravenous TUB-040 every three weeks. TUB-040 is an investigational antibody–drug conjugate targeting NaPi2b that delivers exatecan, a topoisomerase I inhibitor, to tumor cells.

ClinicalTrials.gov ID: NCT06303505

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with inoperable locally advanced, metastatic, or recurrent solid tumors and no effective or tolerable standard options receive intravenous XB010, a 5T4-targeted antibody–drug conjugate carrying the microtubule-disrupting payload monomethyl auristatin E. Dose escalation evaluates XB010 alone or with pembrolizumab; tumor-specific expansion cohorts evaluate XB010 alone in NSCLC, breast, head and neck, esophageal, and endometrial cancers.

ClinicalTrials.gov ID: NCT06545331

A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressive advanced or metastatic solid tumors may receive intravenous OR502, an investigational LILRB2-blocking antibody intended to reduce myeloid immune suppression, alone or with the PD-1 inhibitor cemiplimab. The currently recruiting cohorts are for melanoma and non-small cell lung cancer previously treated with PD-(L)1-based therapy.

ClinicalTrials.gov ID: NCT06090266